175 related articles for article (PubMed ID: 27510692)
1. 'Childhood systemic mastocytosis associated with t (8; 21) (q22; q22) acute myeloid leukemia'.
Rabade N; Tembhare P; Patkar N; Amare P; Arora B; Subramanian PG; Gujral S
Indian J Pathol Microbiol; 2016; 59(3):407-9. PubMed ID: 27510692
[TBL] [Abstract][Full Text] [Related]
2. Systemic mastocytosis with associated acute myeloid leukemia with t (8; 21) (q22; q22).
Gadage VS; Kadam Amare PS; Galani KS; Mittal N
Indian J Pathol Microbiol; 2012; 55(3):409-12. PubMed ID: 23032848
[TBL] [Abstract][Full Text] [Related]
3. Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22).
Johnson RC; Savage NM; Chiang T; Gotlib JR; Cherry AM; Arber DA; George TI
Am J Clin Pathol; 2013 Oct; 140(4):525-35. PubMed ID: 24045550
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.
Xie W; Wang SA; Yin CC; Xu J; Li S; Bueso-Ramos CE; Medeiros LJ; Tang G
Exp Mol Pathol; 2019 Jun; 108():131-136. PubMed ID: 31004601
[TBL] [Abstract][Full Text] [Related]
5. Systemic mastocytosis associated with t(8;21) acute myeloid leukemia in a child: detection of the D816A mutation of KIT.
Yabe M; Masukawa A; Kato S; Yabe H; Nakamura N; Matsushita H
Pediatr Blood Cancer; 2012 Dec; 59(7):1313-6. PubMed ID: 22847983
[TBL] [Abstract][Full Text] [Related]
6. Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia.
Mahadeo KM; Wolgast L; McMahon C; Cole PD
Pediatr Blood Cancer; 2011 Oct; 57(4):684-7. PubMed ID: 21671435
[TBL] [Abstract][Full Text] [Related]
7. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
8. [Acute myeloid leukemia evolving from KIT D816-mutated systemic mastocytosis relapsing two months after completion of chemotherapy].
Harao T; Yamada A; Kinoshita M; Sawa D; Saito Y; Kamimura S; Miyachi H; Ogino T; Kodama Y; Okamoto Y; Kawano Y; Moritake H
Rinsho Ketsueki; 2019; 60(5):378-381. PubMed ID: 31167998
[TBL] [Abstract][Full Text] [Related]
9. Systemic mastocytosis associated with acute myeloid leukemia: case report and implications for disease pathogenesis.
Escribano L; Garca-Montero A; Núñez-López R; López-Jiménez J; Almeida J; Prados A; Orfao A
J Allergy Clin Immunol; 2004 Jul; 114(1):28-33. PubMed ID: 15241340
[TBL] [Abstract][Full Text] [Related]
10. A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation.
Bae MH; Kim HK; Park CJ; Seo EJ; Park SH; Cho YU; Jang S; Chi HS; Lee KH
Ann Lab Med; 2013 Mar; 33(2):125-9. PubMed ID: 23483057
[TBL] [Abstract][Full Text] [Related]
11. Clearance of bone marrow mast cells after hypomethylating agent and venetoclax for systemic mastocytosis associated with myeloid neoplasia.
Pourhassan H; Kim Y; Pullarkat V
Eur J Haematol; 2023 Feb; 110(2):213-216. PubMed ID: 36335580
[TBL] [Abstract][Full Text] [Related]
12. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosis.
Cherian S; McCullouch V; Miller V; Dougherty K; Fromm JR; Wood BL
Cytometry B Clin Cytom; 2016 Jul; 90(4):387-92. PubMed ID: 26525770
[TBL] [Abstract][Full Text] [Related]
14. Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation.
Zuluaga Toro T; Hsieh FH; Bodo J; Dong HY; Hsi ED
Br J Haematol; 2007 Oct; 139(1):31-40. PubMed ID: 17662084
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients.
Won D; Chi HS; Shim H; Jang S; Park CJ; Lee JH
Leuk Res; 2013 Aug; 37(8):883-8. PubMed ID: 23683787
[TBL] [Abstract][Full Text] [Related]
16. Systemic Mastocytosis with Associated Hematological Neoplasms. Diagnostic features and unique response pattern to tyrosine kinase inhibitors and allo-bone marrow transplantation therapy.
Hernández Alconchel I; González de Villambrosía S; Insunza Gaminde A; Montes Moreno S
Rev Esp Patol; 2023; 56(3):180-185. PubMed ID: 37419556
[TBL] [Abstract][Full Text] [Related]
17. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
[TBL] [Abstract][Full Text] [Related]
18. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia.
Kristensen T; Preiss B; Broesby-Olsen S; Vestergaard H; Friis L; Møller MB
Leuk Lymphoma; 2012 Jul; 53(7):1338-44. PubMed ID: 22145956
[TBL] [Abstract][Full Text] [Related]
19. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone.
Pullarkat V; Bedell V; Kim Y; Bhatia R; Nakamura R; Forman S; Sun J; Senitzer D; Slovak ML
Leuk Res; 2007 Feb; 31(2):261-5. PubMed ID: 16876862
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
Ustun C; Corless CL; Savage N; Fiskus W; Manaloor E; Heinrich MC; Lewis G; Ramalingam P; Kepten I; Jillella A; Bhalla K
Leuk Res; 2009 May; 33(5):735-41. PubMed ID: 18986703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
